^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    albumin-bound paclitaxel

    i
    Other names: ABI007, ABI-007, SNA-001, HC007
    Company:
    Generic mfg.
    Drug class:
    Tubulin inhibitor
    Related drugs:
    3d
    Neoadjuvant sintilimab, albumin-bound paclitaxel, and carboplatin for locally advanced, resectable esophageal squamous cell carcinoma: clinical study and mechanistic exploration. (PubMed, NPJ Precis Oncol)
    Proteomic profiling of the TME further elucidates the heterogeneity of immunotherapy responses, offering insights for precision strategies in ESCC neoadjuvant therapy. Trial registration This study was prospectively registered in the Chinese Clinical Trial Registry (ChiCTR2000041081).
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • CD44 (CD44 Molecule)
    |
    PD-L1 expression
    |
    carboplatin • Tyvyt (sintilimab) • albumin-bound paclitaxel
    3d
    Complete Response of Adrenal Metastasis from Pancreatic Cancer Achieved by Multimodal Therapy-A Case Report (PubMed, Gan To Kagaku Ryoho)
    The patient underwent chemoradiotherapy consisting of 60 Gy in 30 fractions combined with gemcitabine+nab-paclitaxel...Histopathological evaluation revealed no viable cancer cells, showing only post-treatment changes, consistent with a pathological complete response(Grade 4). The postoperative course was uneventful, and at 6 months post-adrenalectomy, the patient remains recurrence-free without further adjuvant therapy.
    Journal
    |
    CA 19-9 (Cancer antigen 19-9)
    |
    gemcitabine • albumin-bound paclitaxel • Teysuno (gimeracil/oteracil/tegafur)
    3d
    Iparomlimab and Tuvoraleimab Injection in Combination With Bevacizumab, Albumin-bound Paclitaxel, and Carboplatin as First- or Second-line Treatment for Patients With Advanced Acral and Mucosal Melanoma (clinicaltrials.gov)
    P2, N=48, Not yet recruiting, Fudan University
    New P2 trial
    |
    BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog)
    |
    BRAF mutation
    |
    Avastin (bevacizumab) • carboplatin • albumin-bound paclitaxel • iparomlimab (QL1604)
    3d
    Lingual Nerve Disruption to Augment Neoadjuvant Chemoimmunotherapy in Locally Advanced Tongue Cancer (clinicaltrials.gov)
    P2, N=69, Not yet recruiting, Shanghai Zhongshan Hospital
    New P2 trial
    |
    cisplatin • Tevimbra (tislelizumab-jsgr) • albumin-bound paclitaxel
    4d
    NALIRIFOX versus gemcitabine plus nab-paclitaxel in Chinese patients with advanced pancreatic adenocarcinoma: a randomized, open-label phase II trial. (PubMed, Nat Commun)
    In this phase 2 study (NCT05047991), patients with unresectable metastatic pancreatic adenocarcinoma were randomized to receive NALIRIFOX (liposomal irinotecan, 5-FU, leucovorin, and oxaliplatin) or gemcitabine plus nab-paclitaxel...≥ Grade 3 treatment-emergent adverse events (TEAEs) occurred in 73.1% of patients receiving NALIRIFOX and 84.6% of patients receiving gemcitabine plus nab-paclitaxel, respectively. Despite the premature termination (predetermined sample size of n = 153 not reached) of the study, NALIRIFOX demonstrated improvement in PFS compared with gemcitabine plus nab-paclitaxel, with a manageable safety profile in Chinese patients with advanced pancreatic adenocarcinoma.
    P2 data • Journal
    |
    UGT1A1 (UDP glucuronosyltransferase family 1 member A1)
    |
    gemcitabine • 5-fluorouracil • albumin-bound paclitaxel • oxaliplatin • leucovorin calcium • irinotecan liposomal
    4d
    QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Triple-Negative Breast Cancer (clinicaltrials.gov)
    P2, N=30, Not yet recruiting, Affiliated Hospital of Nantong University
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    HER-2 negative
    |
    carboplatin • doxorubicin hydrochloride • albumin-bound paclitaxel • cyclophosphamide • epirubicin • Qibeian (iparomlimab/tuvonralimab)
    5d
    STAR-121: Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P3, N=1069, Recruiting, Gilead Sciences | Trial completion date: Jun 2028 --> Jan 2029
    Trial completion date • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • RET (Ret Proto-Oncogene) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    BRAF mutation • ALK mutation • RET mutation
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • albumin-bound paclitaxel • pemetrexed • Yutuo (zimberelimab) • domvanalimab (AB154)
    5d
    A Study Evaluating Neoadjuvant Chemotherapy, Concurrent Chemoradiotherapy Combined With Dual Immune Checkpoint Blockade in Patients With Locally Advanced Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=56, Recruiting, Sun Yat-sen University | Not yet recruiting --> Recruiting | Trial completion date: Sep 2029 --> Dec 2029 | Initiation date: Sep 2025 --> Jan 2026 | Trial primary completion date: Sep 2029 --> Dec 2029
    Enrollment open • Trial completion date • Trial initiation date • Trial primary completion date • Checkpoint inhibition
    |
    EGFR (Epidermal growth factor receptor) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    ROS1 wild-type
    |
    Avastin (bevacizumab) • cisplatin • albumin-bound paclitaxel
    5d
    HRS-4642 Combination With Other Antitumor Therapies in Patients With Solid Tumors (clinicaltrials.gov)
    P1/2, N=60, Recruiting, Shanghai Hengrui Pharmaceutical Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    gemcitabine • albumin-bound paclitaxel • AiRuiLi (adebrelimab) • HRS-4642
    5d
    Serplulimab for Locally Advanced Cervical Cancer (clinicaltrials.gov)
    P2, N=216, Recruiting, Tianjin Medical University Cancer Institute and Hospital
    New P2 trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    cisplatin • albumin-bound paclitaxel • Hetronifly (serplulimab)
    5d
    A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene. (clinicaltrials.gov)
    P1, N=26, Active, not recruiting, Pfizer | Recruiting --> Active, not recruiting | N=190 --> 26
    Enrollment closed • Enrollment change • IO biomarker
    |
    KRAS (KRAS proto-oncogene GTPase) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    Keytruda (pembrolizumab) • Avastin (bevacizumab) • Erbitux (cetuximab) • cisplatin • carboplatin • gemcitabine • 5-fluorouracil • albumin-bound paclitaxel • pemetrexed • oxaliplatin • leucovorin calcium • sasanlimab (PF-06801591) • PF-07284892
    5d
    OMO-103-02: Study to Evaluate the Safety, PK, and Efficacy of the Myc Inhibitor OMO-103 Administered iv in Patients With PDAC (clinicaltrials.gov)
    P1, N=26, Active, not recruiting, Peptomyc S.L. | Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2025 --> May 2026
    Enrollment closed • Trial primary completion date
    |
    gemcitabine • albumin-bound paclitaxel • OMO-103